Faeth Therapeutics, Inc. (FTH) - Total Liabilities
Based on the latest financial reports, Faeth Therapeutics, Inc. (FTH) has total liabilities worth $9.58 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. For the complete balance sheet picture, see how large is Faeth Therapeutics, Inc.'s balance sheet.
Faeth Therapeutics, Inc. - Total Liabilities Trend (2018–2025)
This chart illustrates how Faeth Therapeutics, Inc.'s total liabilities have evolved over time, based on quarterly financial data. See Faeth Therapeutics, Inc. short-term liquidity ratio to evaluate short-term liquidity relative to the company's equity base.
Faeth Therapeutics, Inc. Competitors by Total Liabilities
The table below lists competitors of Faeth Therapeutics, Inc. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Arrow Financial Corporation
NASDAQ:AROW
|
USA | $4.04 Billion |
|
Shenzhen TXD Technology Co Ltd
SHE:002845
|
China | CN¥6.72 Billion |
|
Shinkong Textile Co Ltd
TW:1419
|
Taiwan | NT$7.65 Billion |
|
SGC Energy Co Ltd
KO:005090
|
Korea | ₩2.53 Trillion |
|
Beijing Advanced Digital Technology Co Ltd
SHE:300541
|
China | CN¥1.54 Billion |
|
BCI Minerals Limited
F:BC3
|
Germany | €430.26 Million |
|
Shenzhen Properties & Resources Development Group Ltd
SHE:000011
|
China | CN¥11.86 Billion |
|
EZTEC Empreendimentos e Participações S.A
SA:EZTC3
|
Brazil | R$1.79 Billion |
Liability Composition Analysis (2018–2025)
This chart breaks down Faeth Therapeutics, Inc.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. Check FTH financial resilience to evaluate the company's liquid asset resilience ratio.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 19.69 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.06 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.05 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Faeth Therapeutics, Inc.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Faeth Therapeutics, Inc. (2018–2025)
The table below shows the annual total liabilities of Faeth Therapeutics, Inc. from 2018 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $4.31 Million | -38.21% |
| 2024-12-31 | $6.97 Million | -26.42% |
| 2023-12-31 | $9.48 Million | -36.67% |
| 2022-12-31 | $14.97 Million | +123.00% |
| 2021-12-31 | $6.71 Million | +21.26% |
| 2020-12-31 | $5.54 Million | -92.08% |
| 2019-12-31 | $69.88 Million | +26.29% |
| 2018-12-31 | $55.33 Million | -- |
About Faeth Therapeutics, Inc.
Faeth Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of therapeutics for cancer patients. The company offers PIKTOR, an investigational multi-node inhibitor of the PI3K/AKT/mTOR pathway in development for endometrial and breast cancer. It offers Solnerstotug, an active monoclonal antibody that is in clinical Phase 1/2 targeting the immune chec… Read more